Merus (NASDAQ:MRUS) Receives $85.31 Consensus PT from Brokerages

by · The Cerbat Gem

Shares of Merus (NASDAQ:MRUS – Get Free Report) have received an average recommendation of “Buy” from the sixteen analysts that are currently covering the firm, Marketbeat Ratings reports. Fourteen investment analysts have rated the stock with a buy recommendation and two have assigned a strong buy recommendation to the company. The average 1 year target price among analysts that have issued ratings on the stock in the last year is $85.31.

Several equities research analysts have recently weighed in on MRUS shares. The Goldman Sachs Group started coverage on Merus in a research note on Thursday, November 21st. They set a “buy” rating and a $73.00 price objective for the company. William Blair reissued an “outperform” rating on shares of Merus in a research note on Friday, February 28th. Piper Sandler initiated coverage on Merus in a research note on Thursday, February 13th. They set an “overweight” rating and a $84.00 price objective for the company. Guggenheim reaffirmed a “buy” rating on shares of Merus in a research report on Wednesday, February 12th. Finally, Bank of America decreased their target price on Merus from $73.00 to $70.00 and set a “buy” rating for the company in a research report on Monday, March 10th.

Check Out Our Latest Stock Report on Merus

Merus Price Performance

Shares of MRUS stock opened at $47.22 on Thursday. Merus has a 12-month low of $37.77 and a 12-month high of $61.61. The firm has a market capitalization of $3.26 billion, a price-to-earnings ratio of -11.95 and a beta of 1.15. The business has a 50 day simple moving average of $42.99 and a 200 day simple moving average of $46.28.

Merus (NASDAQ:MRUS – Get Free Report) last posted its earnings results on Thursday, February 27th. The biotechnology company reported ($0.41) EPS for the quarter, beating the consensus estimate of ($0.89) by $0.48. Merus had a negative return on equity of 38.89% and a negative net margin of 680.61%. The firm had revenue of $9.14 million for the quarter, compared to analysts’ expectations of $10.57 million. On average, equities analysts anticipate that Merus will post -3.85 EPS for the current fiscal year.

Hedge Funds Weigh In On Merus

Institutional investors have recently bought and sold shares of the stock. State of Wyoming bought a new position in Merus during the fourth quarter valued at about $48,000. Wells Fargo & Company MN increased its stake in shares of Merus by 27.3% in the fourth quarter. Wells Fargo & Company MN now owns 1,400 shares of the biotechnology company’s stock worth $59,000 after purchasing an additional 300 shares during the period. GF Fund Management CO. LTD. bought a new position in shares of Merus in the fourth quarter worth about $60,000. Avior Wealth Management LLC bought a new position in shares of Merus in the fourth quarter worth about $76,000. Finally, Lazard Asset Management LLC bought a new position in shares of Merus in the fourth quarter worth about $84,000. 96.14% of the stock is currently owned by institutional investors.

Merus Company Profile

(Get Free Report

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1.

See Also